keyword
MENU ▼
Read by QxMD icon Read
search

Biochemical relapse of prostate cancer

keyword
https://www.readbyqxmd.com/read/28224113/intensity-modulated-radiation-therapy-with-stereotactic-body-radiation-therapy-boost-for-unfavorable-prostate-cancer-a-report-on-3-year-toxicity
#1
Ima Paydar, Abigail Pepin, Robyn A Cyr, Joseph King, Thomas M Yung, Elizabeth G Bullock, Siyuan Lei, Andrew Satinsky, K William Harter, Simeng Suy, Anatoly Dritschilo, John H Lynch, Thomas P Kole, Sean P Collins
BACKGROUND: Recent data suggest that intensity-modulated radiation therapy (IMRT) plus brachytherapy boost for unfavorable prostate cancer provides improved biochemical relapse-free survival over IMRT alone. Stereotactic body radiation therapy (SBRT) may be a less invasive alternative to brachytherapy boost. Here, we report the 3-year gastrointestinal (GI) and genitourinary (GU) toxicities of IMRT plus SBRT boost. MATERIALS AND METHODS: Between March 2008 and September 2012, patients with prostate cancer were treated with robotic SBRT (19...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28195907/solitary-psma-positive-pulmonary-metastasis-in-biochemical-relapse-of-prostate-cancer
#2
Nils Groe Hokamp, Carsten Kobe, Eric Linzenich, David Maintz, Alexander Drzezga
A 63-year-old man with a history of prostate cancer, treated with resection, radiation, and androgen-depriving therapy over 4 years, was referred to our department with suspicion of recurrence based on increased blood PSA levels (1.60 ng/mL). Ga PSMA PET/CT identified a solitary, PSMA-positive pulmonary nodule in the right lung. After resection, histologic analysis confirmed prostatic origin, and the blood PSA level decreased to 0.13 ng/mL. Solitary pulmonary metastasis from prostate cancer is rare. The benefits of local treatment of a single metastasis even in advanced disease are disputed among oncologists...
February 13, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28139422/salvage-of-locally-recurrent-prostate-cancer-after-external-beam-radiation-using-reduced-dose-brachytherapy-with-neoadjuvant-plus-adjuvant-androgen-deprivation
#3
Brian C Baumann, John C Baumann, John P Christodouleas, Edward Soffen
PURPOSE: Local recurrence (LR) of prostate cancer after external beam radiotherapy (EBRT) is a serious problem. Our purpose was to determine if reduced-dose salvage brachytherapy could achieve high rates of biochemical control with acceptable toxicity if combined with androgen deprivation therapy (ADT). METHODS AND MATERIALS: Thirty-three consecutive patients with LR after EBRT were treated with salvage brachytherapy plus ADT from 1998 to 2013. All had pathologically confirmed LR, disease-free interval ≥18 months after EBRT, no distant/nodal metastasis, and International Prostate Symptom Score ≤15...
January 27, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28139024/anatomic-patterns-of-recurrence-following-biochemical-relapse-after-post-prostatectomy-salvage-radiation-therapy-a-multi-institutional-study
#4
William C Jackson, Neil Desai, Ahmed E Abugharib, Vasu Tumati, Robert T Dess, Jae Y Lee, Shuang G Zhao, Moaaz Soliman, Michael Folkert, Aaron Laine, Raquibul Hannan, Zachary S Zumsteg, Howard Sandler, Daniel A Hamstra, Jeffrey S Montgomery, David C Miller, Mike A Kozminski, Brent K Hollenbeck, Jason W Hearn, Ganesh Palapattu, Scott A Tomlins, Rohit Mehra, Todd M Morgan, Felix Y Feng, Daniel E Spratt
OBJECTIVES: To characterize the frequency and detailed anatomic sites of failure for patients receiving post-radical prostatectomy (RP) salvage radiation therapy (SRT). MATERIALS/METHODS: A multi-institutional retrospective study was performed on 574 men who underwent SRT between 1986 and 2013. Anatomical recurrence patterns were classified as lymphotropic (lymph nodes only), osteotropic (bone only), or multifocal if both were present. Isolated first failure sites were defined as sites of initial clinically detected recurrence that remained isolated for at least 3 months...
January 31, 2017: BJU International
https://www.readbyqxmd.com/read/28134691/parathyroid-adenoma-mimicking-a-malignant-lymph-node-on-18f-choline-pet-ct
#5
Bliede Van den Broeck, Daan De Maeseneer, Ruth De Gersem, Kathia De Man
Prostate carcinoma is the most common cancer in men. After local therapy, disease recurs in many patients. A choline PET/CT is indicated in case of biochemical relapse of prostate carcinoma to determine the site of recurrence (local and/or distant) and to help select the next line of therapy. Choline PET-CT is also known to show an elevated uptake in hyperfunctioning parathyroid adenoma. This case report shows the difficulty to distinguish between both entities if they occur simultaneously in an oncologic patient...
January 27, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28125091/microrna-466-inhibits-tumor-growth-and-bone-metastasis-in-prostate-cancer-by-direct-regulation-of-osteogenic-transcription-factor-runx2
#6
Melissa Colden, Altaf A Dar, Sharanjot Saini, Priya V Dahiya, Varahram Shahryari, Soichiro Yamamura, Yuichiro Tanaka, Gary Stein, Rajvir Dahiya, Shahana Majid
MicroRNAs (miRNAs) have emerged as key players in cancer progression and metastatic initiation yet their importance in regulating prostate cancer (PCa) metastasis to bone has begun to be appreciated. We employed multimodal strategy based on in-house PCa clinical samples, publicly available TCGA cohorts, a panel of cell lines, in silico analyses, and a series of in vitro and in vivo assays to investigate the role of miR-466 in PCa. Expression analyses revealed that miR-466 is under-expressed in PCa compared to normal tissues...
January 26, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28124495/very-high-risk-prostate-cancer-stratification-by-outcomes-of-radiotherapy-and-long-term-androgen-deprivation-therapy
#7
Natsuo Tomita, Norihito Soga, Yuji Ogura, Takumi Kageyama, Takeshi Kodaira
AIM: The definition of very high-risk (VHR) prostate cancer is currently based on the study of radical prostatectomy. We aimed to identify a suitable definition for VHR group following external beam radiation therapy (EBRT) and long-term androgen-deprivation therapy (ADT). METHODS: This retrospective study included 356 high-risk patients treated with EBRT and long-term ADT. A median follow-up time was 68 months. At first, associations of previously described prognostic factors with biochemical disease-free survival (bDFS), clinical relapse-free survival (cRFS) and prostate cancer-specific survival (CSS) were examined...
January 25, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28123863/performance-characteristics-and-relationship-of-psa-value-kinetics-on-carbon-11-acetate-pet-ct-imaging-in-biochemical-relapse-of-prostate-cancer
#8
Fabio D Almeida, Chi-Kwan Yen, Mark C Scholz, Richard Y Lam, Jeffrey Turner, Larry L Bans, Robert Lipson
An elevated serum prostate-specific antigen (PSA) level alone cannot distinguish between local-regional recurrences and distant metastases after treatment with curative intent. With available salvage treatments, it has become important to localize the site of recurrence. (11)C-Acetate PET/CT was performed in patients with rising PSA, with statistical analysis of detection rates, sites/location of detection, PSA kinetics and comparison with other tracers (FDG and Choline). Correlation to biopsy, subsequent imaging and PSA response to focal treatment was also performed...
2017: American Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28115952/salvage-high-dose-rate-brachytherapy-for-histologically-confirmed-macroscopic-local-relapsed-prostate-cancer-after-radical-prostatectomy
#9
David Buchser, Alfonso Gomez-Iturriaga, J Ignacio Rodriguez Melcon, Francisco Casquero, Roberto Llarena, Jon Cacicedo, Pedro Bilbao
PURPOSE: To evaluate the feasibility of the use of real-time magnetic resonance imaging (MRI)-transrectal ultrasound (TRUS) fusion guided high-dose-rate brachytherapy (HDR-BT) +/- external beam radiation therapy (EBRT) in patients with histologically-proven local relapse after radical prostatectomy. MATERIAL AND METHODS: We retrospectively reviewed 13 patients treated with real-time MRI-TRUS fusion HDR-BT for a local relapse of prostate cancer after radical surgery...
December 2016: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/28101585/whole-pelvis-radiotherapy-for-pathological-node-positive-prostate-cancer-oncological-outcome-and-prognostic-factors
#10
Filip Poelaert, Valérie Fonteyne, Piet Ost, Bart De Troyer, Karel Decaestecker, Gert De Meerleer, Pieter De Visschere, Tom Claeys, Bert Dhondt, Nicolaas Lumen
PURPOSE: The goal of this work was to investigate the oncological outcome of whole pelvis radiotherapy (wpRT) in pathologic pelvic lymph node-positive (pN1) prostate cancer (PCa), evaluate the location of relapse, and identify potential prognostic factors. PATIENTS AND METHODS: All patients undergoing pelvic lymph node dissection (PLND) since the year 2000 at a single tertiary care center were evaluated. A total of 154 patients with pN1 PCa were treated with wpRT (39 in an adjuvant setting) and 2-3 years of androgen deprivation therapy (ADT)...
January 18, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28012435/estimation-of-radiation-dosimetry-for-68-ga-hbed-cc-psma-11-in-patients-with-suspected-recurrence-of-prostate-cancer
#11
Mark A Green, Jacob A Eitel, James W Fletcher, Carla J Mathias, Mark A Tann, Thomas Gardner, Michael O Koch, Wendy Territo, Heather Polson, Gary D Hutchins
INTRODUCTION: This study was performed to estimate the human radiation dosimetry for [(68)Ga]Ga-HBED-CC (PSMA-11) ((68)Ga PSMA-11). METHODS: Under an RDRC-approved research protocol, we evaluated the biodistribution and pharmacokinetics of (68)Ga PSMA-11 with serial PET imaging following intravenous administration to nine prostate cancer patients in whom clinical [(11)C]acetate PET/CT exams had been independently performed under Expanded Access IND 118,204. List-mode imaging was performed over the initial 0-10min post-injection with the pelvis in the field-of-view...
November 4, 2016: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/28009150/high-intensity-focused-ultrasound-as-first-line-salvage-therapy-in-prostate-cancer-local-relapse-after-radical-prostatectomy-4-year-follow-up-outcomes
#12
Giuseppe Palermo, Angelo Totaro, Emilio Sacco, Nazario Foschi, Gaetano Gulino, Marco Racioppi, Pierfrancesco Bassi, Francesco Pinto
BACKGROUND: Prostate cancer (PCa) is the most commonly diagnosed malignancy in men and the second leading cause of cancer death in developed countries. Despite the primary treatments, 20-30% of patients experience a recurrence. The main objective of this study was to evaluate the clinical efficacy of salvage high intensity focused ultrasound (HIF U) after radical prostatectomy in terms of biochemical free survival rate (BFSR) and PSA nadir. METHODS: Twenty two patients with local recurrence of Pca after radical prostatectomy underwent HIFU as first-line salvage therapy...
February 2017: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/27986374/evaluating-the-effect-of-time-from-prostate-cancer-diagnosis-to-radical-prostatectomy-on-cancer-control-can-surgery-be-postponed-safely
#13
Nicola Fossati, Martina Sofia Rossi, Vito Cucchiara, Giorgio Gandaglia, Paolo Dell'Oglio, Marco Moschini, Nazareno Suardi, Federico Dehò, Francesco Montorsi, Riccardo Schiavina, Alexandre Mottrie, Alberto Briganti
OBJECTIVE: To test the prognostic role of treatment delay in patients affected by prostate cancer (PCa). MATERIALS AND METHODS: The study included 2,653 patients treated with radical prostatectomy (RP) at a single institution between 2006 and 2011. The evaluated outcomes were biochemical recurrence (BCR) and clinical recurrence (CR). Multivariable Cox regression analysis was used to test the association between time from diagnosis to RP and oncological outcomes...
December 13, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27976632/evaluation-of-99-m-tc-labeled-psma-spect-ct-imaging-in-prostate-cancer-patients-who-have-undergone-biochemical-relapse
#14
Heng-Chuan Su, Yao Zhu, Guo-Wen Ling, Si-Long Hu, Xiao-Ping Xu, Bo Dai, Ding-Wei Ye
Using conventional imaging modalities, it is difficult to detect recurrent lesions in prostate cancer patients who have undergone biochemical relapse, especially in patients with low prostate-specific antigen (PSA) levels. We retrospectively reviewed the files of fifty patients with histopathologically confirmed prostate cancer who underwent [99]m Tc-labeled prostate-specific membrane antigen (PSMA) single-photon emission computed tomography (SPECT)/computed tomography (CT), magnetic resonance imaging (MRI), and bone scan within a 30-day period...
December 13, 2016: Asian Journal of Andrology
https://www.readbyqxmd.com/read/27908968/psa-stratified-performance-of-18f-and-68ga-labeled-tracers-in-psma-pet-imaging-of-patients-with-biochemical-recurrence-of-prostate-cancer
#15
Felix Dietlein, Carsten Kobe, Stephan Neubauer, Matthias Schmidt, Simone Stockter, Thomas Fischer, Klaus Schomäcker, Axel Heidenreich, Boris D Zlatopolskiy, Bernd Neumaier, Alexander Drzezga, Markus Dietlein
PURPOSE: Several studies outlined the sensitivity of (68)Ga-labeled PET tracers against the prostate-specific membrane antigen (PSMA) for localization of relapsed prostate cancer in patients with renewed increase in the prostate-specific antigen (PSA), commonly referred to as biochemical recurrence. Labeling of PSMA tracers with (18)F offers numerous advantages, including improved image resolution, longer half-life and increased production yields. The aim of this study was to assess the PSA-stratified performance of the (18)F-labeled PSMA tracer (18)F-DCFPyL and the (68)Ga-labeled reference (68)Ga-PSMA-HBED-CC...
December 1, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27902483/androgen-receptor-phosphorylation-status-at-serine-578-predicts-poor-outcome-in-prostate-cancer-patients
#16
Patek Sc, Willder Jm, Heng Js, Taylor B, Horgan Pg, Leung Hy, Underwood Ma, Edwards J
PURPOSE: Prostate cancer growth is dependent upon androgen receptor (AR) activation, regulated via phosphorylation. Protein kinase C (PKC) is one kinase that can mediate AR phosphorylation. This study aimed to establish if AR phosphorylation by PKC is of prognostic significance. METHODS: Immunohistochemistry for AR, AR phosphorylated at Ser-81 (pARS81), AR phosphorylated at Ser-578 (pARS578), PKC and phosphorylated PKC (pPKC) was performed on 90 hormone-naïve prostate cancer specimens...
November 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27900519/early-dynamic-imaging-in-68-ga-psma-11-pet-ct-allows-discrimination-of-urinary-bladder-activity-and-prostate-cancer-lesions
#17
Christian Uprimny, Alexander Stephan Kroiss, Clemens Decristoforo, Josef Fritz, Boris Warwitz, Lorenza Scarpa, Llanos Geraldo Roig, Dorota Kendler, Elisabeth von Guggenberg, Jasmin Bektic, Wolfgang Horninger, Irene Johanna Virgolini
PURPOSE: PET/CT with (68)Ga-labelled prostate-specific membrane antigen (PSMA)-ligands has been proven to establish a promising imaging modality in the work-up of prostate cancer (PC) patients with biochemical relapse. Despite a high overall detection rate, the visualisation of local recurrence may be hampered by high physiologic tracer accumulation in the urinary bladder on whole body imaging, usually starting 60 min after injection. This study sought to verify whether early dynamic (68)Ga-PSMA-11 (HBED-CC)PET/CT can differentiate pathologic PC-related tracer uptake from physiologic tracer accumulation in the urinary bladder...
November 29, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27896369/detection-rate-of-pet-ct-in-patients-with-biochemical-relapse-of-prostate-cancer-using-68-ga-psma-i-t-and-comparison-with-published-data-of-68-ga-psma-hbed-cc
#18
Christoph Berliner, Milena Tienken, Thorsten Frenzel, Yuske Kobayashi, Annabelle Helberg, Uve Kirchner, Susanne Klutmann, Dirk Beyersdorff, Lars Budäus, Hans-Jürgen Wester, Janos Mester, Peter Bannas
PURPOSE: To determine the detection rate of PET/CT in biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and to compare it with published detection rates of [(68)Ga]PSMA HBED-CC. METHODS: We performed a retrospective analysis in 83 consecutive patients with documented biochemical relapse after prostatectomy. All patients underwent whole body [(68)Ga]PSMA I&T PET/CT. PET/CT images were evaluated for presence of local recurrence, lymph node metastases, and distant metastases...
November 28, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27878044/a-comparative-study-of-radical-prostatectomy-and-permanent-seed-brachytherapy-for-low-and-intermediate-risk-prostate-cancer
#19
Daniel Taussky, Véronique Ouellet, Guila Delouya, Fred Saad
INTRODUCTION: We sought to compare the outcomes between radical prostatectomy (RP) and permanent seed prostate brachytherapy (PB) in patients with low- and low-intermediate-risk prostate cancer from a single tertiary care centre. METHODS: Patients were selected from our institute's internal database based on preoperative selection criteria from the National Comprehensive Cancer Network (NCCN) guidelines (2015) for low- and intermediate-risk patients. No patient had received any neo-adjuvant androgen-deprivation therapy...
August 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/27815082/translating-a-prognostic-dna-genomic-classifier-into-the-clinic-retrospective-validation-in-563-localized-prostate-tumors
#20
Emilie Lalonde, Rached Alkallas, Melvin Lee Kiang Chua, Michael Fraser, Syed Haider, Alice Meng, Junyan Zheng, Cindy Q Yao, Valerie Picard, Michele Orain, Helène Hovington, Jure Murgic, Alejandro Berlin, Louis Lacombe, Alain Bergeron, Yves Fradet, Bernard Têtu, Johan Lindberg, Lars Egevad, Henrik Grönberg, Helen Ross-Adams, Alastair D Lamb, Silvia Halim, Mark J Dunning, David E Neal, Melania Pintilie, Theodorus van der Kwast, Robert G Bristow, Paul C Boutros
BACKGROUND: Localized prostate cancer is clinically heterogeneous, despite clinical risk groups that represent relative prostate cancer-specific mortality. We previously developed a 100-locus DNA classifier capable of substratifying patients at risk of biochemical relapse within clinical risk groups. OBJECTIVE: The 100-locus genomic classifier was refined to 31 functional loci and tested with standard clinical variables for the ability to predict biochemical recurrence (BCR) and metastasis...
November 1, 2016: European Urology
keyword
keyword
111181
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"